Lung Cancer | Specialty

Alectinib Highly Effective for ALK+ NSCLC With CNS Metastases

September 8th 2017

Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Bunn on the Response of Immunotherapy in Lung Cancer

September 7th 2017

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the response of immunotherapy in patients with lung cancer.

Frontline Icotinib Improves PFS Versus Chemo in EGFR+ NSCLC

September 6th 2017

Icotinib (Conmana) was associated with a 3.3-month increase in median progression-free survival compared with chemotherapy in patients with stage IIIB/IV non–small cell lung cancer.

Dr. Vokes on the Standard of Care for Stage III NSCLC

September 1st 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non

Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

September 1st 2017

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

September 1st 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Dr. Garon on Antiangiogenic Agents in Lung Cancer

September 1st 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Pembrolizumab Shows Promise in Small Cell Lung Cancer

August 31st 2017

Pembrolizumab induced an overall response rate of 33% in patients with extensive-stage small cell lung cancer.

Dr. Bunn on the MYSTIC Trial for Lung Cancer

August 31st 2017

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Researcher Highlights Emerging Role of RET Inhibitors in NSCLC

August 29th 2017

Christine M. Lovly, MD, PhD, discusses the importance of identifying and targeting RET in non-small cell lung cancer.

Liquid Biopsy for NSCLC: Emerging Developments

August 29th 2017

Future Directions for Liquid Biopsy in NSCLC

August 29th 2017

Liquid Biopsy and Next-Generation Sequencing

August 29th 2017

Interpretation of NSCLC Plasma Genotyping Results

August 29th 2017

Liquid Biopsy: Differences Among Technologies

August 29th 2017

Plasma Genotyping Platforms: Strengths and Limitations

August 29th 2017

Plasma Testing for NSCLC EGFR & ALK Mutations

August 29th 2017

Clinical Applications for NSCLC Liquid Biopsy

August 29th 2017

How Does Liquid Biopsy Work?

August 29th 2017